KIF11 and cancer: Although the clinical development of Eg5 inhibitors (e.g., ispinesib, filanesib, and litronesib) has faced challenges, including dose-limiting neutropenia, inconsistent efficacy across cancer subtypes, and acquired resistance mechanisms, these limitations highlight the need for novel stents with better selectivity and pharmacokinetic profiles.